Legato Capital Management LLC Purchases Shares of 142,164 Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

Legato Capital Management LLC bought a new stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 142,164 shares of the company's stock, valued at approximately $482,000. Legato Capital Management LLC owned about 0.10% of Xeris Biopharma at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in XERS. Wealth Enhancement Advisory Services LLC purchased a new position in Xeris Biopharma in the third quarter valued at about $35,000. R Squared Ltd purchased a new position in Xeris Biopharma in the fourth quarter valued at about $42,000. Quantbot Technologies LP purchased a new stake in shares of Xeris Biopharma during the third quarter worth about $44,000. Sanctuary Advisors LLC purchased a new stake in shares of Xeris Biopharma during the second quarter worth about $75,000. Finally, Janney Montgomery Scott LLC grew its stake in shares of Xeris Biopharma by 31.4% during the fourth quarter. Janney Montgomery Scott LLC now owns 23,000 shares of the company's stock worth $78,000 after acquiring an additional 5,500 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company's stock.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on XERS shares. Jefferies Financial Group restated a "buy" rating and set a $6.00 price target (up previously from $4.00) on shares of Xeris Biopharma in a research note on Wednesday, January 29th. Piper Sandler lowered Xeris Biopharma from an "overweight" rating to a "neutral" rating and set a $3.00 price target on the stock. in a research note on Monday, November 11th. Finally, HC Wainwright boosted their price target on Xeris Biopharma from $6.00 to $6.60 and gave the stock a "buy" rating in a research note on Monday, November 11th.

Xeris Biopharma Stock Performance

NASDAQ XERS traded up $0.20 during trading hours on Tuesday, reaching $3.79. The stock had a trading volume of 1,832,312 shares, compared to its average volume of 1,498,591. The stock has a fifty day moving average of $3.45 and a 200 day moving average of $3.12. The stock has a market cap of $564.27 million, a P/E ratio of -8.41 and a beta of 2.61. Xeris Biopharma Holdings, Inc. has a 52-week low of $1.69 and a 52-week high of $3.87.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.